Antibody drug conjugates (ADCs) are projected to dominate the $3.9 billion NSCLC market by 2032. Despite a historical lack of ADC presence in NSCLC, recent approvals like AstraZeneca and Daiichi Sankyo’s Enhertu signify a turning point in targeting HER2-mutated tumors.
Read more about this — thepharmaletter.com